DK3310389T3 - Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis - Google Patents

Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis Download PDF

Info

Publication number
DK3310389T3
DK3310389T3 DK16729470.1T DK16729470T DK3310389T3 DK 3310389 T3 DK3310389 T3 DK 3310389T3 DK 16729470 T DK16729470 T DK 16729470T DK 3310389 T3 DK3310389 T3 DK 3310389T3
Authority
DK
Denmark
Prior art keywords
retinoid
corticosteroid
psoriasis
treatment
compositions including
Prior art date
Application number
DK16729470.1T
Other languages
Danish (da)
English (en)
Inventor
Gordon J Dow
Radhakrishnan Pillai
Varsha Bhatt
Original Assignee
Bausch Health Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56131662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3310389(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bausch Health Ireland Ltd filed Critical Bausch Health Ireland Ltd
Application granted granted Critical
Publication of DK3310389T3 publication Critical patent/DK3310389T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK16729470.1T 2015-06-18 2016-06-06 Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis DK3310389T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562181481P 2015-06-18 2015-06-18
PCT/US2016/035991 WO2016205001A1 (en) 2015-06-18 2016-06-06 Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis

Publications (1)

Publication Number Publication Date
DK3310389T3 true DK3310389T3 (da) 2020-08-10

Family

ID=56131662

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16729470.1T DK3310389T3 (da) 2015-06-18 2016-06-06 Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis

Country Status (20)

Country Link
US (7) US10251895B2 (https=)
EP (1) EP3310389B1 (https=)
JP (1) JP6997624B2 (https=)
KR (2) KR102643849B1 (https=)
CN (1) CN108282998B (https=)
AU (1) AU2016279801B2 (https=)
BR (1) BR112017027332B1 (https=)
CA (1) CA2988577A1 (https=)
CY (1) CY1123354T1 (https=)
DK (1) DK3310389T3 (https=)
ES (1) ES2812451T3 (https=)
HR (1) HRP20201250T1 (https=)
HU (1) HUE050603T2 (https=)
LT (1) LT3310389T (https=)
MX (1) MX377544B (https=)
PL (1) PL3310389T3 (https=)
PT (1) PT3310389T (https=)
RS (1) RS60672B1 (https=)
SI (1) SI3310389T1 (https=)
WO (1) WO2016205001A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
JP6997624B2 (ja) * 2015-06-18 2022-01-17 ボシュ ヘルス ユーエス，エルエルシー． 乾癬を治療するためのコルチコステロイドおよびレチノイドを含む局所用組成物
WO2017011600A1 (en) * 2015-07-13 2017-01-19 Dr. Reddy's Laboratories, Ltd. Topical retinoid compositions
JP7410720B2 (ja) * 2017-05-12 2024-01-10 ボシュ ヘルス アイルランド リミテッド 皮膚疾患を治療するための局所組成物および方法
US11311482B2 (en) * 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
HUE055016T2 (hu) * 2017-06-23 2021-10-28 Salvat Lab Sa Olaj-a-vízben nanoemulziós klobetazol készítmény
US11364198B2 (en) * 2018-04-05 2022-06-21 Bausch Health Ireland Limited Polymeric emulsion delivery systems
US10653656B2 (en) 2018-04-05 2020-05-19 Bausch Health Ireland Limited Topical pharmaceutical compositions for treating skin conditions
JP2022525221A (ja) 2019-03-14 2022-05-11 クレシタ セラピューティクス インコーポレイテッド 洗い流し組成物および活性剤を送達するためのそれらの使用
KR102327827B1 (ko) 2019-11-01 2021-11-18 한국과학기술연구원 강황 추출물을 유효성분으로 포함하고 자외선 처리를 포함하는 건선 개선용 조성물
CN113116891B (zh) * 2019-12-30 2024-07-16 重庆华邦制药有限公司 一种乳膏及其制备方法
KR102451304B1 (ko) 2020-09-14 2022-10-07 한국과학기술연구원 꿩의다리속 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102461001B1 (ko) 2020-09-14 2022-11-01 한국과학기술연구원 술패랭이꽃 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102527907B1 (ko) 2020-09-14 2023-05-03 한국과학기술연구원 무산상자 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102692893B1 (ko) 2021-09-17 2024-08-08 한국과학기술연구원 시미시푸고라이드 에이를 유효성분으로 포함하는 건선 개선용 조성물
KR102769642B1 (ko) 2021-09-17 2025-02-20 한국과학기술연구원 눈개승마 추출물을 유효성분으로 포함하는 건선 개선용 조성물
CN113975249B (zh) * 2021-10-14 2023-01-03 中山大学·深圳 Tris-BNP纳米颗粒的制备及其在皮肤疾病治疗中的应用
CN113712918A (zh) * 2021-10-28 2021-11-30 济南纽华医药科技有限公司 一种阿普斯特微乳及其制备方法
WO2024141639A1 (en) * 2022-12-31 2024-07-04 Bausch Health Ireland Limited Use of a fixed combination of halobetasol propionate and tazarotene to treat conditions mediated by interleukin-17a
WO2024201481A1 (en) * 2023-03-29 2024-10-03 Scires Technologies Private Limited Anti-psoriasis topical formulation containing combination drugs and method of preparation thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU75903A1 (https=) 1976-09-29 1978-05-16
NL7105591A (en) 1971-04-24 1972-10-26 Topical antiphlogistic compsns - contng 3, 20-diketo-9 alpha, 11 beta-dichloro - 16 alpha, 17 alpha-dimethyl-21-hydroxy pregna-1,4-
DE2655570A1 (de) 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
US4083974A (en) 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
JPS5850964B2 (ja) 1978-03-07 1983-11-14 東興薬品工業株式会社 ステロイド含有クリ−ム製剤およびその製造方法
US4299828A (en) 1979-05-31 1981-11-10 E. R. Squibb & Sons, Inc. Corticosteroid stick formulations
AU5794680A (en) 1979-05-31 1980-12-04 E.R. Squibb & Sons, Inc. Corticosteroid stick formulations
US4233295A (en) 1979-05-31 1980-11-11 E. R. Squibb & Sons, Inc. Corticosteroid formulations containing sebacate carrier
PT73772B (en) 1980-10-06 1983-10-14 Glaxo Group Ltd Topically administrable pharmaceutical compositions containing anti-inflammatory steroids
JPS58225009A (ja) 1982-06-23 1983-12-27 Shionogi & Co Ltd コルチコステロイド外用製剤
DE3225848A1 (de) 1982-07-07 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Kortikoidhaltige zubereitung zur topischen applikation
GB8401965D0 (en) 1984-01-25 1984-02-29 Beecham Group Plc Composition
CA1303991C (en) 1986-03-31 1992-06-23 Chung H. Cheng Composition and method for delivering a steroid active ingredient
US5019569A (en) 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy
JPH0676327B2 (ja) 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイド軟膏製剤
JPH0676328B2 (ja) 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイドクリ−ム製剤
JPH07116026B2 (ja) 1987-07-07 1995-12-13 株式会社資生堂 ジクロフェナックナトリウム含有乳化外用剤
US5422361A (en) 1989-12-20 1995-06-06 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
WO1991012821A1 (fr) 1990-03-02 1991-09-05 Shiseido Company, Ltd. Composition d'emulsion aqueuse contenant un analgesique anti-inflammatoire steroidien
TW218849B (https=) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
JP4387463B2 (ja) 1997-02-20 2009-12-16 アラーガン、インコーポレイテッド タザロテンおよびコルチコステロイドによる乾癬の処置
SE9800729L (sv) 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
GB9823036D0 (en) 1998-10-22 1998-12-16 Glaxo Group Ltd Fluticasone lotion having improved vasoconstrictor activity
AU2877800A (en) * 1999-02-12 2000-08-29 Susan Bershad Short contact treatment of psoriasis with topical retinoids
US6730308B1 (en) * 1999-03-08 2004-05-04 Allergan, Inc. Tazarotene and alpha hydroxy acid treatment for psoriasis and/or photodamage
US6656928B1 (en) 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US6479058B1 (en) 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
KR100844285B1 (ko) * 2000-10-27 2008-07-09 레오 파마 에이/에스 하나 이상의 비타민 ｄ 또는 비타민 ｄ 동족체 및 하나이상의 코르티코스테로이드를 함유하는 국부용 조성물
US6709663B2 (en) 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
US6765001B2 (en) 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US7544674B2 (en) 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
CN1210034C (zh) * 2002-12-06 2005-07-13 重庆华邦制药股份有限公司 治疗银屑病的药物组合物
AU2003302305A1 (en) 2002-12-31 2004-07-22 Sachin S Bhagwat Benzoquinolizine-2-carboxylic acid-containing compositions
JP2004359585A (ja) 2003-06-03 2004-12-24 Medorekkusu:Kk 被膜形成型の副腎皮質ステロイド薬含有外用製剤
CN1210041C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗痤疮的复方外用药物
CN1210035C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗银屑病的复方外用药物
US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
JPWO2006098353A1 (ja) 2005-03-15 2008-08-28 協和醗酵工業株式会社 外用剤
TW200740441A (en) 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
CA2633464A1 (en) 2005-12-14 2007-09-07 Zars Pharma, Inc. Compositions and methods for dermal delivery of drugs
WO2008038147A2 (en) 2006-07-05 2008-04-03 Foamix Ltd. Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
EP2097065A2 (en) 2006-11-29 2009-09-09 Foamix Ltd. Foamable waterless compositions with modulating agents
RU2470645C2 (ru) 2007-09-10 2012-12-27 Гленмарк Фармасьютикалс Лимитед Фармацевтическая композиция для местного применения, содержащая комбинацию фузидовой кислоты и кортикостероида
WO2009084020A2 (en) 2007-10-18 2009-07-09 Glenmark Pharmaceuticals Limited Topical composition comprising halobetasol and salicylic acid
KR101848095B1 (ko) 2008-06-26 2018-04-11 안테리오스, 인코퍼레이티드 경피 운반
PT2400951T (pt) 2009-02-25 2018-11-26 Mayne Pharma Llc Composições de espuma tópica
US20130310355A1 (en) 2009-12-15 2013-11-21 Young Pharmaceuticals, Inc. Low toxicity topical active agent delivery system
WO2012051614A2 (en) 2010-10-15 2012-04-19 Kulesza John E Delivery of hydrophobic bioactive agents
EP2635276B1 (en) * 2010-11-04 2017-07-19 442 Ventures, LLC Composition and its use in method for treating skin conditions
US8809307B2 (en) * 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US9034926B2 (en) * 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
TW201311295A (zh) 2011-06-03 2013-03-16 Allergan Inc 對皮脂腺之類視色素化合物之目標遞送
BR112014015578A8 (pt) 2012-01-09 2017-07-04 Almirall Sa composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
US8962028B2 (en) 2012-10-18 2015-02-24 MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company Topical steroid composition and method
CN104288157B (zh) * 2013-01-29 2018-04-13 江苏知原药业有限公司 包含丙酸氯倍他索和维a酸的固体分散体及其制备方法
BR112016006830A2 (pt) * 2013-09-25 2017-08-01 Sun Pharmaceutical Ind Ltd composição de spray tópico de halobetasol, sistema de distribuição para a administração da composição, processo para a preparação de uma composição de spray tópico, método para o tratamento de condições de pele tópicas
JP6997624B2 (ja) 2015-06-18 2022-01-17 ボシュ ヘルス ユーエス，エルエルシー． 乾癬を治療するためのコルチコステロイドおよびレチノイドを含む局所用組成物
US20190133943A1 (en) 2015-06-18 2019-05-09 Valeant Pharmaceuticals North America Topical compositions and methods for treating skin diseases
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
JP7410720B2 (ja) 2017-05-12 2024-01-10 ボシュ ヘルス アイルランド リミテッド 皮膚疾患を治療するための局所組成物および方法

Also Published As

Publication number Publication date
SI3310389T1 (sl) 2020-11-30
US20180177803A1 (en) 2018-06-28
US20230086282A1 (en) 2023-03-23
JP2018526325A (ja) 2018-09-13
EP3310389B1 (en) 2020-07-01
JP6997624B2 (ja) 2022-01-17
WO2016205001A1 (en) 2016-12-22
EP3310389A1 (en) 2018-04-25
US10251895B2 (en) 2019-04-09
PL3310389T3 (pl) 2020-11-30
CY1123354T1 (el) 2021-12-31
BR112017027332B1 (pt) 2023-11-07
US11679116B2 (en) 2023-06-20
HRP20201250T1 (hr) 2020-11-13
MX2017015990A (es) 2018-11-09
AU2016279801A1 (en) 2018-01-04
KR102643849B1 (ko) 2024-03-07
US20210145847A1 (en) 2021-05-20
US20230355640A1 (en) 2023-11-09
LT3310389T (lt) 2020-11-10
AU2016279801B2 (en) 2021-09-09
US20210330681A1 (en) 2021-10-28
CN108282998B (zh) 2021-07-06
HUE050603T2 (hu) 2020-12-28
CA2988577A1 (en) 2016-12-22
RS60672B1 (sr) 2020-09-30
US10426787B2 (en) 2019-10-01
KR20180053292A (ko) 2018-05-21
KR102779108B1 (ko) 2025-03-07
ES2812451T3 (es) 2021-03-17
US20190231797A1 (en) 2019-08-01
CN108282998A (zh) 2018-07-13
US11648256B2 (en) 2023-05-16
US11679115B2 (en) 2023-06-20
PT3310389T (pt) 2020-11-11
BR112017027332A2 (pt) 2018-09-04
MX377544B (es) 2025-03-10
US20160367570A1 (en) 2016-12-22
KR20240035898A (ko) 2024-03-18

Similar Documents

Publication Publication Date Title
DK3310389T3 (da) Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis
DK3212226T3 (da) Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3426859T3 (da) Gipspanel, anvendelse af et sådant panel og fremgangsmåde til fremstilling af et sådant panel
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
KR20180084891A (ko) 구조 조성물 및 방법
PL3362987T3 (pl) Układ i sposób korekcji obrazu
DK3155101T3 (da) Sammensætninger og fremgangsmåder til ekspression af CRISPR-leder-RNA´er under anvendelse af H1-promotoren
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3144001T3 (da) Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3143217T3 (da) Akustisk panel og fremgangsmåde til at forbedre æstetikken af et akustisk panel
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3524255T3 (da) Sammensætning til behandling af acne
DK4434585T3 (da) Forbindelser og fremgangsmåder til reduktion af snca-ekspression
DK3157534T3 (da) Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3229840T3 (da) 3,5-dihydroxy-4-isopropyl-trans-stilben til anvendelse i topisk behandling af akne
PL3198460T3 (pl) Aparat i sposób konfiguracji zbiorów przerwań
DK3261644T3 (da) Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3288379T3 (da) Peptidsammensætninger og anvendelsesmåder
DK3212776T3 (da) Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3265057T3 (da) Topisk formulering
DK3273951T3 (da) Sammensætninger og fremgangsmåder til behandling af psoriasis